dm+d

30427009

Articles

Safety in Lactation: Acne and rosacea

30 October 2020Topical preparations for acne are considered to pose a negligible risk to a breastfeeding infant as long as precautions are taken to avoid contact of…

What is the optimal prokinetic dose of erythromycin in adults?

22 October 2020This updated Medicines Q&A evaluates the available evidence for the use of erythromycin as a prokinetic agent in adults Summary The ideal prokinetic dose of…

Safety in Lactation: Macrolides

21 October 2020Epidemiologic evidence indicates that the risk of hypertrophic pyloric stenosis in infants might be increased by use of maternal macrolides, especially in infants exposed in…

Is there an interaction between erythromycin and statins?

2 October 2020This updated Medicines Q&A evaluates the evidence for an interaction between erythromycin and statins. Summary: Erythromycin raises the plasma levels of statins which are metabolised…

What is the most suitable treatment for acne in a person with acute porphyria?

10 January 2020Topical (applied to the skin) treatments for acne are considered to be safer than oral treatments in people with an acute form of porphyria, provided…
Search Articles

Medicine Compliance Aid Stability

genericAurobindo Pharma - Milpharm Ltd

Aurobindo Pharma - Milpharm Ltd
generic
Tablets 250mg
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
Airtight container
Protect from moisture
Protect from light. Protect from moisture. Airtight container.
4 March 2015

Erythroped AAmdipharm Mercury Co Ltd

Amdipharm Mercury Co Ltd
Erythroped A
Tablets 500mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from moisture
Protect from light & store in airtight container. Protect from moisture.
12 March 2015

ErymaxCephalon (UK) Ltd

Cephalon (UK) Ltd
Erymax
Capsules g/r 250mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from moisture
Hygroscopic. Protect from light & store in airtight container. Maximum 7 days in MCA.
4 August 2016

Lactation Safety Information

Oral / Intravenous

Oral / Intravenous
Limited published evidence of safety
Small amounts in breast milk
Used in full-term neonates from birth
One case report of hypertrophic pyloric stenosis, and additional minor adverse effects, in a breastfed infant
23 September 2020

Topical

Topical
Yes
Minimal systemic absorption by mother
23 September 2020